Navigation Links
Data Show Dutasteride Reduces Prostate Cancer Diagnosis in Men With Increased Risk
Date:4/28/2009

REDUCE Trial data presented during American Urological Association Annual Meeting, April 27

CHICAGO, April 28 /PRNewswire-USNewswire/ -- Dutasteride (Avodart), a commonly prescribed drug to treat benign prostatic hyperplasia, has been shown to lower the risk of prostate cancer by 23 percent in men with an increased risk of the disease, according to results of an international clinical trial presented yesterday at the American Urological Association (AUA) Annual Meeting in Chicago. Data from the REDUCE Trial was presented to members during the plenary session, and lead investigator Gerald Andriole, MD, of Washington University School of Medicine in St. Louis, held a special session for interested media at 12:15 p.m. in the AUA Press Suite.

The REDUCE trial is the first to examine chemoprevention for prostate cancer in men at increased risk for the disease. The trial involved 8,200 men ages 50 - 75 who were randomly assigned to receive a placebo or a daily 0.5 mg dose of dutasteride. Men in the study had elevated PSA levels (2.5 - 10 ng/ml) indicating that they were at increased risk of prostate cancer. They had undergone biopsies that found no evidence of cancer within six months prior to enrolling in the trial. Therefore these men either did not have prostate cancer or possibly had microscopic tumors that were too small to be detected by the pre-study biopsy.

The investigators performed scheduled biopsies on the men two years after they enrolled in the study and again after four years. After two years, prostate cancer was found in 17.2 percent of the men who took a placebo, compared with 13.4 percent who took dutasteride. After four years, prostate cancer was diagnosed in another 11.8 percent of men who received a placebo and 9.1 percent who received dutasteride.

"In these men, the most likely explanation is that dutasteride worked by shrinking tumors and/or slowing their growth, thereby making them less likely to be detected by a biopsy," Dr. Andriole said. "This drug has the potential to offer many thousands of men a way to reduce their risk of being diagnosed with prostate cancer and, as a result, more men could avoid treatment for prostate cancer and the cost and unwanted side effects associated with treatment."

The investigators found that there was no greater risk for the men who did develop prostate cancer to have aggressive tumors. This outcome was closely watched because an earlier trial of a similar BPH drug - finasteride (Proscar) - produced controversial results with regard to the risk of more aggressive tumors in those men who developed prostate cancer while on finasteride. An initial analysis of the finasteride data suggested that there was an increased risk for men to have prostate cancer with higher Gleason scores but a later analysis suggested that there is probably no greater risk for these men to develop higher grade prostate cancer.

Over the course of the current study, 6.8 percent of men in the placebo group and 6.7 percent of men in the dutasteride group were found to have aggressive, high-grade tumors, defined as a Gleason score of 7 - 10.

"We are very encouraged by this finding," Dr. Andriole says. "Clearly, the data show dutasteride did not lead to more high-grade tumors, even though they would have been easier to detect in the dutasteride-treated men due to their smaller prostates."

The REDUCE (Reduction by Dutasteride of Prostate Cancer Events) trial was conducted at 250 sites in 42 countries around the world. The study was funded by GlaxoSmithKline. Dr. Andriole is chairman of the REDUCE steering committee and a consultant for the company.

For more information about this presentation, please contact AUA Communications Manager Wendy Waldsachs Isett at 410-977-4770.

About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is the pre-eminent professional organization for urologists, with more than 16,000 members throughout the world. An educational nonprofit organization, the AUA pursues its mission of fostering the highest standards of urologic care by carrying out a wide variety of programs for members and their patients.

    Contact:
    Wendy Waldsachs Isett, AUA
    Cell: 410-977-4770

    AUA On-Site Press Suite
    312-528-8253


'/>"/>
SOURCE American Urological Association
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New study: Pine bark reduces perimenopausal symptoms
2. Different method of evaluating the urinary tract system reduces radiation dose
3. Saline Reduces Mortality for Brain Injury Patients
4. New study: Pine bark extract reduces ADHD symptoms in children
5. Radiation therapy technique reduces length of prostate cancer treatment
6. Radiation therapy technique reduces length of prostate cancer treatment
7. MR spectroscopy identifies breast cancer, reduces biopsies
8. Body-mind meditation boosts performance, reduces stress
9. Parkinsons Institute research shows that nicotine reduces levodopa-induced dyskinesias
10. VIDEO from Medialink and EcoQuest: New Technology Reduces Exposure to MRSA Staph
11. Ranexa(R) Significantly Reduces Incidence of CV Death, MI or Recurrent Ischemia in MERLIN TIMI-36 Patients With Elevated BNP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... ... AlignLife clinics nationwide are giving back to their communities by collecting toys ... gifts wrapped tightly under a Christmas Tree. AlignLife hopes to spread the joy ... In exchange for generous donations, customers will receive a gift in return. Anyone ...
(Date:12/7/2016)... ... ... Facial plastic surgeon, Dr. John D. Rachel of Timeless You™ Chicago , ... local organizations: North Chicago Animal Control and Friends and Our House of Hope Rescue. ... and trained volunteers who support rescued animals held in the City of North Chicago’s ...
(Date:12/7/2016)... California (PRWEB) , ... December 07, 2016 , ... "ProBrand ... any and all media," said Christina Austin - CEO of Pixel Film Studios. , ... with easy to use drop zones. Editors can select from a variety of flip ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Tomorrow Trump Goes To Washington”: a brief ... the presidency and to America. “Tomorrow Trump Goes To Washington” is the creation of ... can for this country. , Nancy attributes her patriotic nature to her WWII veteran ...
(Date:12/7/2016)... WI (PRWEB) , ... December 07, 2016 , ... ... Labs, was honored to present at the International Probiotic Association’s Washington DC workshop ... and government regulators to engage in dialog regarding probiotic dietary supplement regulations. ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... , Dec. 6, 2016 Radioisotopes are ... Radioisotopes are produced either by using nuclear research reactor ... the form of alpha, beta or gamma when changed ... are used in Nuclear medicine, specifically in medical diagnostics. ... diagnostic information about a human body,s functioning. Radiotherapy is ...
(Date:12/6/2016)... Dec. 6, 2016 Human Vaccines Market: ... region wise and country wise analysis of the ... manufacturers of human vaccines products, raw material suppliers, ... enter the market. The report provides qualitative ... market. Qualitative analysis comprises market dynamics, trends, product ...
(Date:12/6/2016)... Two new disaster drones delivered telemedical packages ... casualty event Tuesday at John Bell Airport in ... an audience including Mississippi Governor ... Federal Law Enforcement Agencies, and the United Nations. ... Integrated Rescue Operations), was developed by Italo Subbarao ...
Breaking Medicine Technology: